Table 2 Dual- versus single-targeted CAR-T cell therapy for relapsed or refractory large cell lymphoma
CD19/22 | CD19/CD20 | Axi-Cel | Tisa-Cel | Liso-Cel | |
|---|---|---|---|---|---|
(Alexander) | (Zuma-1) | (Juliet) | (Transcend) | ||
Phase | 1 | 1 | 2 | 2 | 2 |
Patients (n) | 33 | 12 | 111 | 93 | 256 |
Target | CD19, CD22 | CD19, CD20 | CD19 | CD19 | CD19 |
Co-stim | OX40, 41BB | 41BB | CD28 | 41BB | 41BB |
CR | 52% | 42% | 52% | 40% | 53% |
Median PFS (month) | NA | NA | 5.9 | 3 | 6.8 |
Median OS (month) | NA | NA | NR | 12 | 21.1 |
CRS, any grade | 33% | 42% | 93% | 58% | 42% |
≥ 3 | NA | 0 | 13% | 22% | 2% |
Neurotoxicity any grade | 9% | 8% | 64% | 21% | 30% |
≥ 3 | 0 | 0 | 28% | 13% | 10% |
References | [33] | [34] | [30] | [8] | [5] |
ASH 2020, #600 | ASH 2020, #404 | NEJM, 2017 | NEJM, 2019 | Lancet, 2020 |